The legal battle surrounding access to the abortion medication mifepristone has once again reached the United States Supreme Court. Two pharmaceutical manufacturers, Danco Laboratories and GenBioPro, have submitted an emergency appeal requesting the apex court to pause a recent ruling by the 5th Circuit Court of Appeals. This lower court decision temporarily reinstated a mandate requiring the drug to be dispensed in person, effectively halting mail-order and telehealth distributions. Legal analysts note that the manufacturers argue the appellate order introduces unprecedented confusion and disrupts highly time-sensitive medical care, requesting an administrative stay while the justices review the case.
The appellate court’s decision has drawn sharp criticism from prominent figures and reproductive rights organizations. Philanthropist Melinda French Gates publicly condemned the ruling, describing it as a severe setback for families and warning that restricting access to this essential medication will only make healthcare more dangerous for women in vulnerable situations. Similarly, Nancy Northup, chief executive of the Center for Reproductive Rights, argued that the move selectively targets abortion patients by dismantling telehealth, which has become a vital lifeline since federal abortion protections were overturned in 2022. The American Civil Liberties Union also criticized the ruling, characterizing it as an attempt to impose medically unjustified restrictions under the guise of an upcoming federal review.
The current legal turmoil traces back to a lawsuit filed by the state of Louisiana in October 2025, which actively sought to revive the in-person dispensing requirement. The drug manufacturers contend that Louisiana is not obligated by the federal government to prescribe or utilize the medication, urging the Supreme Court to dismiss the state’s standing in a manner consistent with a related 2024 ruling against medical groups.
Conversely, conservative lawmakers and anti-abortion advocacy groups have welcomed the 5th Circuit’s intervention. The Alliance Defending Freedom publicly celebrated the ruling, while US Senator Steve Daines praised the halt of mail-order distribution, arguing that the unrestricted shipping of the pills across state lines endangered women and facilitated unregulated procedures. The manufacturers’ emergency appeal is expected to be handled initially by Justice Samuel Alito, who authored the landmark 2022 decision that ended federal abortion rights, and who is anticipated to request a formal response from Louisiana officials before the court takes further action.
